Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CATX | PRESS-RELEASE | neutral | 3/10 | Perspective Therapeutics announced that data from its lapemelanotide zapixetar ([²¹²Pb]VMT01) program for metastatic mel | Oct 2, 2026 |
| BIIB | PRESS-RELEASE | bullish | 6/10 | Biogen announced positive 52-week Phase 2 data for litifilimab in cutaneous lupus erythematosus (CLE), showing continued | Oct 2, 2026 |
| INKT | PRESS-RELEASE | neutral | 4/10 | MiNK Therapeutics presented preclinical data at SITC 2026 showing agenT-797 enables tumor-cell killing in a checkpoint i | Oct 2, 2026 |
| IMRX | PRESS-RELEASE | neutral | 3/10 | Immuneering announced a poster presentation at SITC 2026 showing that atebimetinib enhances PD-1 checkpoint blockade in | Oct 2, 2026 |
| EVAX | PRESS-RELEASE | neutral | 4/10 | Evaxion announced new immune data from its phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma will | Oct 2, 2026 |
| IPSC | PRESS-RELEASE | bullish | 4/10 | Century Therapeutics presented preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diab | Oct 2, 2026 |
| TEVA | PRESS-RELEASE | bullish | 5/10 | Teva announced a peer-reviewed publication in the Journal of Child Neurology summarizing the neurobiological rationale a | Oct 2, 2026 |
| TEVA | PRESS-RELEASE | bullish | 6/10 | Teva presented new Phase 2b/3 and open-label extension data for ecopipam (D1 antagonist) in pediatric Tourette syndrome | Oct 2, 2026 |
| SRZN | PRESS-RELEASE | bullish | 6/10 | Surrozen received FDA clearance to begin clinical trials of SZN-8141 for diabetic macular edema, a key pipeline mileston | Oct 2, 2026 |
| IFRX | PRESS-RELEASE | neutral | 3/10 | InflaRx announced that its oral C5aR1 antagonist izicopan was selected for a late-breaking poster at ASN Kidney Week 202 | Oct 2, 2026 |
| PYXS | PRESS-RELEASE | bearish | 7/10 | Pyxis Oncology closed a ~$110M public offering on October 1, 2026, selling 36M shares and pre-funded warrants for 1.9M s | Oct 2, 2026 |
| CGEM | PRESS-RELEASE | bullish | 7/10 | Cullinan Therapeutics announced initiation of an NDA submission to the FDA for zipalertinib plus chemotherapy in first-l | Oct 1, 2026 |
| ZNTL | PRESS-RELEASE | neutral | 2/10 | Zentalis Pharmaceuticals granted inducement stock options for 62,000 shares to three newly hired employees under the 202 | Oct 1, 2026 |
| SGMT | PRESS-RELEASE | bearish | 6/10 | Sagimet Biosciences closed a $115M underwritten offering of 8.75M shares of Series A common stock and pre-funded warrant | Oct 1, 2026 |
| ADRX | PRESS-RELEASE | bullish | 7/10 | ADARx Pharmaceuticals announced the full exercise of the underwriters' option to purchase an additional 3,937,500 shares | Oct 1, 2026 |
| NBTX | PRESS-RELEASE | neutral | 2/10 | Nanobiotix announced the appointment of Arnd Christ as CFO, replacing Bart Van Rhijn. The filing is a routine executive | Oct 1, 2026 |
| QCLS | PRESS-RELEASE | neutral | 3/10 | Q/C Technologies announced a collaboration with Sandia National Laboratories' Center for Integrated Nanotechnologies (CI | Oct 1, 2026 |
| REGN | PRESS-RELEASE | bullish | 6/10 | Regeneron announced first clinical data for ubamatamab (MUC16xCD3 bispecific) in low-grade serous ovarian cancer (LGSOC) | Oct 1, 2026 |
| REGN | PRESS-RELEASE | bullish | 6/10 | Regeneron announced positive Phase 2 COURAGE trial results for trevogrumab (anti-myostatin) showing preservation of lean | Oct 1, 2026 |
| GANX | PRESS-RELEASE | neutral | 4/10 | Gain Therapeutics presented Phase 1b open-label extension data for rexaceract (GT-02287) at the MDS Congress, showing MD | Oct 1, 2026 |
| ERNA | PRESS-RELEASE | neutral | 4/10 | Ernexa Therapeutics announced the appointment of Dr. Robert J. Spiegel to its Board of Directors and provided a pipeline | Oct 1, 2026 |
| BCDA | PRESS-RELEASE | bullish | 7/10 | BioCardia announced it has completed a revised De Novo pre-submission to the FDA's CDRH for its Helix Catheter, a device | Oct 1, 2026 |
| TOMZ | PRESS-RELEASE | neutral | 3/10 | TOMI Environmental Solutions announced growing adoption of its SteraMist iHP technology in India's pharmaceutical sector | Oct 1, 2026 |
| GEVO | PRESS-RELEASE | bullish | 5/10 | Gevo sold substantially all of its 2026 Section 45Z tax credits for $70 million, receiving over $30 million in cash thro | Oct 1, 2026 |
| HRMY | PRESS-RELEASE | neutral | 3/10 | Harmony Biosciences announced a poster presentation at the 17th European Narcolepsy Days featuring data from its ongoing | Oct 1, 2026 |
| CADL | PRESS-RELEASE | bullish | 7/10 | Candel Therapeutics announced peer-reviewed publication of final Phase 2a data for aglatimagene besadenovec plus valacyc | Oct 1, 2026 |
| ABUS | PRESS-RELEASE | bullish | 7/10 | Arbutus Biopharma completed a modified Dutch auction tender offer, repurchasing 46 million shares for $230 million at $5 | Oct 1, 2026 |
| IFRX | PRESS-RELEASE | neutral | 2/10 | InflaRx announced the appointment of Dr. Gabriela Alperovich as SVP & Global Head of Clinical Development, effective Oct | Oct 1, 2026 |
| GENB | PRESS-RELEASE | bullish | 5/10 | Generate Biomedicines announced the first patient dosed in a Phase 1 trial of GB-5267, an AI-designed IL-18 armored CAR | Oct 1, 2026 |
| FATE | PRESS-RELEASE | neutral | 2/10 | Fate Therapeutics announced management participation in Q4 2026 investor conferences. No financial results or material b | Oct 1, 2026 |